Sai Life Sciences has allotted 8,89,133 equity shares under ESOP on 19 December 2025. Powered by Capital Market - Live News

Net profit of Sai Life Sciences rose 101.98% to Rs 83.84 crore in the quarter ended September 2025 as against Rs 41.51 crore during the previous quarter ended September 2024. Sales rose 35.88% to Rs 537.47 crore in the quarter ended September 2025 as against Rs 395.56 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales537.47395.56 36 OPM %27.1325.84 - PBDT151.8091.24 66 PBT112.0555.32 103 NP83.8441.51 102 Powered by Capital Market - Live News

Sai Life Sciences will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live News

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing. Through this partnership, customers will have access to integrated drug substance and drug product development, helping them move efficiently from preclinical studies to first-in-human (FIH) clinical trials and beyond. Powered by Capital Market - Live News

Sai Life Sciences has allotted 1,50,500 equity shares under ESOP on 03 September 2025. Powered by Capital Market - Live News